Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Cogent Biosciences (COGT) announced that CEO Andrew Robbins will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 7:30 a.m. PT. A live webcast will be accessible on the company’s website, with a replay available post-event for 30 days. Cogent focuses on precision therapies for genetically defined diseases, notably developing bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation. The company aims to address serious diseases like systemic mastocytosis and advanced gastrointestinal stromal tumors.
- CEO Andrew Robbins will present at a major healthcare conference, increasing visibility.
- Cogent is developing bezuclastinib, a targeted therapy for serious diseases.
- None.
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2023 at 7:30 a.m. PT/10:30 a.m. ET. A live webcast of the presentation will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
When is the Cogent Biosciences presentation at the J.P. Morgan Healthcare Conference?
What is bezuclastinib developed by Cogent Biosciences?
Where can I watch the Cogent Biosciences conference presentation?
How long will the webcast replay of the Cogent presentation be available?
